DUBLIN, Ohio — Cardinal Health and Hellman & Friedman (H&F) announced Monday the completion of the previously announced sale of Cardinal Health’s Cordis business to H&F. The sale price of approximately $1 billion includes the buyer’s assumption of certain liabilities and the seller’s retention of certain working capital accounts. “We appreciate H&F’s partnership throughout the transaction,
DUBLIN, Ohio — Cardinal Health has completed its acquisition of Johnson & Johnson’s Cordis cardiology and endovascular device business for $1.944 billion. Cardinal said Sunday evening that the integration of Cordis off to a strong start, with management teams in place worldwide. The company noted that planning has been ongoing since the deal was announced
DUBLIN, Ohio — Cardinal Health Inc. has closed its $1.115 billion acquisition of pharmaceutical distributor Harvard Drug Group. Cardinal said Monday that the all-cash deal, announced in early June, will boost its generic drug distribution business as well as expand its over-the counter drug product offerings and its telesales programs and capabilities. Harvard Drug also
DUBLIN, Ohio — Cardinal Health Inc. plans to acquire pharmaceutical distributor The Harvard Drug Group (THDG) from private equity firm Court Square Capital Partners for $1.12 billion. Based in Livonia, Mich., THDG is a distributor of generic drugs, over-the-counter medicines and related products to retail, institutional and alternate care customers. THDG had revenue of about
DUBLIN, Ohio — Cardinal Health Inc. plans to acquire cardiology and endovascular device maker Cordis from Johnson & Johnson for $1.944 billion. Cardinal said Monday that the cash deal would significantly advance its offering of interventional cardiology and endovascular solutions for integrated health systems and their patients by giving the company immediate global scale in
